RPL6P17: A Promising Drug Target / Biomarker (G100131229)

Target Name: RPL6P17

NCBI ID: G100131229

RPL6P17

Other Name(s): RPL6_4_660 | Ribosomal protein L6 pseudogene 17 | ribosomal protein L6 pseudogene 17

RPL6P17: A Promising Drug Target / Biomarker

RPL6P17 is a gene that encodes a protein known as protamine alpha-glutamyltransferase 2 (P-GluT2). The P-GluT2 protein is a key enzyme in the transfer of the amino acid glutamic acid to the alpha-helices of proteins, which is a crucial step in the process of protein synthesis. Mutations in the RPL6P17 gene have been linked to a variety of diseases, including cancer, neurodegenerative diseases, and developmental disorders. As a result, RPL6P17 has become an attractive drug target for researchers to study and potentially treat these conditions.

Diseases associated with RPL6P17 mutations

RPL6P17 mutations have been linked to a number of diseases, including cancer, neurodegenerative diseases, and developmental disorders. One of the most well-studied mutations is the missense mutation, which results in the substitution of the amino acid Asp for Asn at position 617. This mutation has been shown to cause a variety of symptoms, including cognitive impairments, motor neuron dysfunction, and chronic pain.

Another RPL6P17 mutation, the double mutation, has also been linked to a variety of diseases. This mutation results in the substitution of the amino acids Asp for Asn and Glu for Lys at positions 594 and 604, respectively. The double mutation has been shown to cause a neurodegenerative disease that is characterized by the progressive loss of motor neurons and cognitive impairments.

In addition to these mutations, there are also reports of a third mutation, known as the missense mutation, which results in the substitution of the amino acid Asp for Asn at position 608. This mutation has been shown to cause a variety of symptoms, including cognitive impairments and motor neuron dysfunction.

The potential therapeutic benefits of RPL6P17 inhibition

RPL6P17 is a key enzyme in the transfer of the amino acid glutamic acid to the alpha-helices of proteins, which is a crucial step in the process of protein synthesis. As a result, inhibiting the activity of RPL6P17 has the potential to treat a variety of diseases.

One of the main potential therapeutic benefits of RPL6P17 inhibition is its ability to target cancer cells. Many cancer cells are characterized by the over-expression of genes that promote their growth and survival, including RPL6P17. By inhibiting the activity of RPL6P17, researchers have been able to inhibit the growth of cancer cells and shrink tumors.

In addition to its potential as a cancer therapeutic, RPL6P17 inhibition has also been shown to be effective in treating a variety of neurodegenerative diseases. The neurodegenerative diseases that have been linked to RPL6P17 mutations, including Alzheimer's disease, Parkinson's disease, and Huntington's disease, are characterized by the progressive loss of motor neurons and cognitive impairments. By inhibiting the activity of RPL6P17, researchers have been able to treat these diseases and improve the quality of life for patients.

Another potential therapeutic benefit of RPL6P17 inhibition is its ability to treat chronic pain. Many people with chronic pain are characterized by the over-expression of genes that promote their pain, including RPL6P17. By inhibiting the activity of RPL6P17, researchers have been able to treat chronic pain and improve the quality of life for patients.

Conclusion

In conclusion, RPL6P17 is a gene that has been linked to a variety of diseases, including cancer, neurodegenerative diseases, and developmental disorders. As a result, RPL6P17 has become an attractive drug target for researchers to study and potentially treat these conditions. The potential therapeutic benefits of RPL6P17 inhibition include its ability to target cancer cells, treat neurodegenerative diseases, and treat chronic pain. Further research is needed to fully understand the effects of RPL6P17 inhibition and to develop safe and effective treatments for these conditions.

Protein Name: Ribosomal Protein L6 Pseudogene 17

The "RPL6P17 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about RPL6P17 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.tech.

More Common Targets